inspection – Page 72

Validation gaps identified during system upgrades – preventing repeat validation findings

Addressing Validation Gaps Identified During System Upgrades for Optimal Compliance In the fast-evolving landscape of pharmaceutical manufacturing, system upgrades are a necessity but often result in validation gaps that can…

Archival process non-compliant during sponsor oversight – evidence package inspectors expect

Addressing Non-Compliance in Archival Processes During Sponsor Oversight In the highly regulated pharmaceutical environment, the pivotal role of archival processes cannot be emphasized enough. These processes ensure that data integrity…

Record retention failures during system upgrade – CAPA and revalidation strategy

Strategies for Managing Record Retention Failures During System Upgrades In the ever-evolving landscape of pharmaceutical manufacturing, the integrity of electronic records is paramount. Record retention failures during a system upgrade…

Requalification overdue during site expansion – regulatory deficiency risk

Addressing Requalification Issues during Site Expansion to Mitigate Regulatory Risks As pharmaceutical manufacturing facilities expand, the urgency to maintain Good Manufacturing Practice (GMP) compliance increases, particularly concerning validation and requalification…

ERES controls not implemented during compliance audit – inspection evidence requirements

Managing ERES Controls Lapses During Compliance Audits: Your Playbook In an increasingly regulated environment, pharmaceutical manufacturers face mounting pressure to ensure robust compliance with Electronic Records and Electronic Signatures (ERES)…

Incomplete validation lifecycle during change control – risk-based validation alignment

Aligning the Validation Lifecycle with Change Control: A Practical Playbook In the pharmaceutical manufacturing world, ensuring a complete and compliant validation lifecycle during change control is paramount for maintaining product…

ERES controls not implemented during system operation – risk-based ERES remediation

Remediation for ERES Control Failures During System Operation In the evolving landscape of pharmaceutical manufacturing, the implementation of effective electronic records and electronic signatures (ERES) controls is critical. When ERES…

Change impact not assessed during system upgrades – risk-based validation alignment

Assessing Change Impact During System Upgrades: A Playbook for GMP Compliance In the dynamic landscape of pharmaceutical manufacturing, system upgrades are pivotal yet often overlooked for their potential impact on…

Archival process non-compliant during internal audit – evidence package inspectors expect

Addressing Non-Compliance in Archival Processes: A Playbook for Effective Internal Audits As pharmaceutical organizations strive to adhere to stringent regulatory standards, issues related to archival process compliance can pose significant…

System access controls weak during system upgrade – inspection evidence requirements

Strengthening System Access Controls During Upgrades: An Inspection-Ready Playbook Pharmaceutical manufacturers frequently confront challenges when upgrading electronic systems. A particularly critical issue arises when system access controls are weak during…

Incomplete validation lifecycle during lifecycle management – CAPA and revalidation strategy

Managing Incomplete Validation Lifecycles in Pharmaceutical Operations Incomplete validation lifecycles can pose significant risks to pharmaceutical manufacturing operations, leading to potential regulatory non-compliance and gaps in product quality assurance. This…

ERES controls not implemented during inspection walkthrough – risk-based ERES remediation

Handling Incomplete ERES Controls During Inspection Walkthroughs: A Comprehensive Playbook The pharmaceutical industry is under increasing scrutiny for the management of Electronic Records and Electronic Signatures (ERES). When ERES controls…